Novartis has launched its FocalView app, an ophthalmic digital research platform, to allow researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients.
By adapting the design of clinical trials to suit the daily routine of patients, the app may reduce barriers to participation, according to the company. FocalView aims to help patients complete various assessments, gaining feedback on their visual function, including any changes over time. At the same time, the app could provide researchers with a greater volume of real-world, patient-reported data, creating more flexible and accessible clinical trial designs.
Novartis plans to test FocalView in a prospective, non-interventional study to evaluate the app’s efficacy and usability in assessing visual function. These measurements include visual acuity and contrast sensitivity. Researchers will in turn assess ease of use, level of enrollment and the ability to obtain important documentation for future clinical trial research, such as informed consent. In the next phase, the app will be validated against traditional visual testing that takes place within conventional clinical settings.
FocalView is now available for download from the App Store in the U.S. Consent to contribute to research data will be required before a user can interact with the tool.